Evidence map›Paper›PMID 41872508›Full record

Articlenpj metabolic health and disease2026

An IL6 variant -174 G-C alters cardiac hypertrophy but not cardiometabolic responses to HFD in mice.

L E Watson, M Annandale, C L MacRae, J Bai, J Dayaram, N Burgess, C Puliuvea, P Kallingappa, C P Hedges, R F D'Souza and 4 more

Abstract read
In one paragraph

Article in npj metabolic health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

L E WatsonDepartment of Nutrition, University of Auckland, Auckland, New Zealand. lauren.watson@auckland.ac.nz.
M AnnandaleDepartment of Physiology, University of Auckland, Auckland, New Zealand.
C L MacRaeDepartment of Nutrition, University of Auckland, Auckland, New Zealand.
J BaiDepartment of Physiology, University of Auckland, Auckland, New Zealand.
J DayaramDepartment of Physiology, University of Auckland, Auckland, New Zealand.
N BurgessDepartment of Physiology, University of Auckland, Auckland, New Zealand.
C PuliuveaDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.
P KallingappaFaculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
C P HedgesDepartment of Nutrition, University of Auckland, Auckland, New Zealand.
R F D'SouzaDepartment of Nutrition, University of Auckland, Auckland, New Zealand.
K L WeeksDepartment of Anatomy & Physiology, University of Melbourne, Victoria, Australia.
N FlemingMaurice Wilkins Centre of Research Excellence (CoRE), Auckland, New Zealand.
T L MerryDepartment of Nutrition, University of Auckland, Auckland, New Zealand. t.merry@auckland.ac.nz.
K M MellorDepartment of Physiology, University of Auckland, Auckland, New Zealand. k.mellor@auckland.ac.nz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic elevations in interleukin-6 (IL6) signaling have been shown to exacerbate features of cardiometabolic disease. A common variant in the IL6 promoter (location -174 G/C, identifier rs1800795) is associated with increased circulating IL6, and increased cardiometabolic disease incidence in some populations. This study's objective was to isolate the impact of this gene variant on cardiometabolic responses to metabolic stress, using knock-in mice with a GG wildtype or variant CC genotype for the murine homolog of rs1800795. Male and female IL6 variant CC mice on a high fat diet exhibited enhanced systemic IL6 levels but similar weight gain, energy expenditure, adipose tissue inflammation, glucose homeostasis, and cardiac function relative to control GG mice. Sex differences in the effect of the IL6 variant on cardiomyocyte dimensions were observed, with male variant mice exhibiting smaller cardiomyocyte volume, and female variant mice exhibiting larger cardiomyocyte volume with smaller raw heart mass relative to control GG mice. These findings suggest that, in a controlled experimental setting, the IL6 promoter variant (-174 G/C) does not increase susceptibility to cardiometabolic disease. Further work is required to understand the mechanistic link between this IL6 variant and associated increased cardiometabolic risk observed in population studies.

Identifiers

PMID41872508
PMCPMC13009176

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.